RapidAI’s Rapid Hyperdensity Tool Receives FDA Clearance

July 21, 2022—RapidAI, a California-based company focused on neurovascular and vascular artificial intelligence (AI)–enhanced clinical decision support and patient workflow technology, announced it has received FDA clearance for Rapid Hyperdensity, the newest addition to the RapidAI platform.

According to the company, the tool empowers physicians to quickly assess the severity of injury in patients with acute neuro conditions such as traumatic brain injury and brain hemorrhages, thereby allowing for better and faster patient care decisions.

The AI-powered Rapid Hyperdensity tool uses noncontrast CT scans to quickly assess the volume of hyperdense tissue in the brain to help physicians identify the extent of an intracerebral hemorrhage (ICH). For hospitals and mobile stroke units on the front lines of patient assessment, Rapid Hyperdensity provides additional contextual data to help physicians make more informed triage and transfer decisions to get patients to the right place more efficiently.

In the press release, the company noted the following key benefits of Rapid Hyperdensity:

• Automated detection of intracranial hyperdensities > 1 mL
• Quick identification of hyperdense volumes to improve hemorrhage management
• Fast results that can be viewed via the Rapid mobile app, PACS/Workstation, or email

“As a neurosurgeon who treats many patients with ICH, I am very excited for the recently approved Rapid Hyperdensity product that builds on the well-established RapidAI stroke platform,” commented Alejandro M. Spiotta, MD, in the company’s press release. “Detection of ICH via AI can save lives by helping to speed up diagnosis and accelerate transfer to the best physician and hospital that can take care of the patient.”

Dr. Spiotta, who is Director of the Neuroendovascular Surgery Division at the Medical University of South Carolina in Charleston, South Carolina, continued, “With the addition of automatic hyperdense volume measurement, physicians can more easily track volume over time and help quickly identify which patients may require an intervention. This is an exciting time for those of us treating ICH.”